STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Molecular Biotechnological Research Original Research

Integrating Network Pharmacology and Molecular Docking to Investigate Boerhavia diffusa for Pancreatic Cancer Treatment

  1. Gouri Anil Department of Biotechnolgy, People's Education Society University, Bangalore

Abstract

Objective: In this study, network pharmacology was applied to determine the therapeutic effects of the bioactive compounds of Boerhavia diffusa. Network pharmacology can unearth the underlying mechanisms between drugs and the disease targets and aids in the discovery of novel medications for complex conditions such as cancer.

Methods: To predict the molecular mechanisms of action of Boerhavia diffusa in the treatment of was screened using the GeneCards database. The Venn diagram was used to identify the intersecting targets of Boerhavia diffusa and Alzheimer’s disease. The obtained target information was entered into the STRING database to construct a protein-protein interaction network. Database for Annotation, Visualization, and Integrated Discovery (DAVID) database was used to perform the GO and KEGG Pathway Enrichment analysis. Cytoscape Software was used to construct the networks, and the key targets were identified. The binding affinity of the bioactive compounds of Boerhavia diffusa with the target proteins was analyzed. PyRx, an online tool was used to perform molecular docking. It was performed using protein structures from the Protein Data Bank (PDB) Database and PubChem. BIOVIA Discovery Studio software was used to analyze the protein structure.

Result: Upon performing molecular docking, the proteins AKT1, epidermal growth factor receptor (EGFR), and STAT3 have the best binding affinities with the bioactive compounds of Boerhavia diffusa.

Conclusion: According to the results, the phytocompounds have potential therapeutic effects which provide insight into the theoretical basis for the investigation of the pharmacological mechanism of Boerhavia diffusa. Alzheimer’s disease using network pharmacology, the phytocompounds were obtained from the IMPPAT database. Target information for the phytocompounds and Alzheimer’s disease

Keywords

References (76)

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians. 2005;55(2):74-108. doi:10.3322/canjclin.55.2.74
  2. Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J. Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages. PLoS Medicine. 2010;7(4):e1000267. doi:10.1371/journal.pmed.1000267
  3. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. The Lancet. 2016;388(10039):73-85. doi:10.1016/s0140-6736(16)00141-0
  4. He J. Management of borderline and locally advanced pancreatic cancer: Where do we stand? World Journal of Gastroenterology. 2014;20(9):2255. doi:10.3748/wjg.v20.i9.2255
  5. Seufferlein T, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treatment Reviews. 2019;77:1-10. doi:10.1016/j.ctrv.2019.05.007
  6. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology. 2011;29(31):4105-4112. doi:10.1200/jco.2011.34.8904
  7. Zhen DB, Coveler A, Zanon S, Reni M, Chiorean EG. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. Seminars in Oncology. 2018;45(3):107-115. doi:10.1053/j.seminoncol.2018.05.004
  8. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet. 2020 Jun 27;395(10242):2008-20.
  9. Sherman MH, Beatty GL. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annual Review of Pathology: Mechanisms of Disease. 2023;18(1):123-148. doi:10.1146/annurev-pathmechdis-031621-024600
  10. Beatty GL, Werba G, Lyssiotis CA, Simeone DM. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes & Development. 2021;35(13-14):940-962. doi:10.1101/gad.348523.121
  11. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72(1):7-33. doi:10.3322/caac.21708
  12. Conklin KA. Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness. Integrative Cancer Therapies. 2004;3(4):294-300. doi:10.1177/1534735404270335
  13. Jaiswal YS, Williams LL. A glimpse of Ayurveda – The forgotten history and principles of Indian traditional medicine. Journal of Traditional and Complementary Medicine. 2017;7(1):50-53. doi:10.1016/j.jtcme.2016.02.002
  14. Dutta R, Khalil R, Green R, Mohapatra SS, Mohapatra S. Withania Somnifera (Ashwagandha) and Withaferin A: Potential in Integrative Oncology. International Journal of Molecular Sciences. 2019;20(21):5310. doi:10.3390/ijms20215310
  15. Shimizu T, Torres MP, Chakraborty S, Souchek JJ, Rachagani S, Kaur S, et al. Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: Potential role in therapy. Cancer Letters. 2013;336(2):270-280. doi:10.1016/j.canlet.2013.03.017
  16. Akimoto M, Iizuka M, Kanematsu R, Yoshida M, Takenaga K. Anticancer Effect of Ginger Extract against Pancreatic Cancer Cells Mainly through Reactive Oxygen Species-Mediated Autotic Cell Death. PLOS ONE. 2015;10(5):e0126605. doi:10.1371/journal.pone.0126605
  17. Rao SK, Rao PS, Rao BN. Preliminary investigation of the radiosensitizing activity of guduchi (Tinospora Cordifolia) in tumor‐bearing mice. Phytotherapy Research. 2008;22(11):1482-1489. doi:10.1002/ptr.2508
  18. Poornima P, Efferth T. Ayurveda for Cancer Treatment. Medicinal & Aromatic Plants. 2016;5(5). doi:10.4172/2167-0412.1000e178
  19. Govindarajan R, Vijayakumar M, Pushpangadan P. Antioxidant approach to disease management and the role of ‘Rasayana’ herbs of Ayurveda. Journal of Ethnopharmacology. 2005;99(2):165-178. doi:10.1016/j.jep.2005.02.035
  20. Bairwa K, Srivastava A, Jachak SM. Quantitative Analysis of Boeravinones in the Roots of Boerhaavia Diffusa by UPLC/PDA. Phytochemical Analysis. 2014;25(5):415-420. doi:10.1002/pca.2509
  21. Srivastava R, Saluja D, Chopra M. Isolation and screening of anticancer metabolites from Boerhavia diffusa. Indian J Med Res. 2005;151(Suppl 1).
  22. Mungantiwar AA, Nair AM, Kamal KK, Saraf MN. Adaptogenic activity of aqueous extract of the roots of Boerhaavia diffusa Linn. Indian Drugs. 1997;34:184-9.
  23. Karole S, Shrivastava S, Thomas S, Soni B, Khan S, Dubey J, et al. Polyherbal Formulation Concept for Synergic Action: A Review. Journal of Drug Delivery and Therapeutics. 2019;9(1-s):453-466. doi:10.22270/jddt.v9i1-s.2339
  24. Hopkins AL. Network pharmacology. Nature Biotechnology. 2007;25(10):1110-1111. doi:10.1038/nbt1007-1110
  25. Zhang B, Wang X, Li S. An Integrative Platform of TCM Network Pharmacology and Its Application on a Herbal Formula,Qing-Luo-Yin. Evidence-Based Complementary and Alternative Medicine. 2013;2013:1-12. doi:10.1155/2013/456747
  26. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466-2472. doi:10.1093/bioinformatics/btp465
  27. Kibble M, Saarinen N, Tang J, Wennerberg K, Mäkelä S, Aittokallio T. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Natural Product Reports. 2015;32(8):1249-1266. doi:10.1039/c5np00005j
  28. Liu X, Zhou H. Application of proteomics technique in study of network pharmacology. Prog Pharm Sci. 2014;38:89–96.
  29. Mohanraj K, Karthikeyan BS, Vivek-Ananth RP, Chand RPB, Aparna SR, Mangalapandi P, et al. IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry And Therapeutics. Scientific Reports. 2018;8(1). doi:10.1038/s41598-018-22631-z
  30. Barton HA, Pastoor TP, Baetcke K, Chambers JE, Diliberto J, Doerrer NG, et al. The Acquisition and Application of Absorption, Distribution, Metabolism, and Excretion (ADME) Data in Agricultural Chemical Safety Assessments. Critical Reviews in Toxicology. 2006;36(1):9-35. doi:10.1080/10408440500534362
  31. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports. 2017;7(1). doi:10.1038/srep42717
  32. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research. 2021;49(W1):W5-W14. doi:10.1093/nar/gkab255
  33. Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V. SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Research. 2014;42(W1):W32-W38. doi:10.1093/nar/gku293
  34. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nature Biotechnology. 2007;25(2):197-206. doi:10.1038/nbt1284
  35. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Current Protocols in Bioinformatics. 2016;54(1). doi:10.1002/cpbi.5
  36. Oliveros JC. Venny. An interactive tool for comparing lists with Venn’s diagrams. 2007–15. Available from: https://bioinfogp.cnb.csic.es/tools/venny/index.html.
  37. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biology. 2003;4(9). doi:10.1186/gb-2003-4-9-r60
  38. Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, et al. SRplot: A free online platform for data visualization and graphing. PLOS ONE. 2023;18(11):e0294236. doi:10.1371/journal.pone.0294236
  39. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research. 2003;13(11):2498-2504. doi:10.1101/gr.1239303
  40. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Systems Biology. 2014;8(S4). doi:10.1186/1752-0509-8-s4-s11
  41. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research. 2018;47(D1):D607-D613. doi:10.1093/nar/gky1131
  42. RCSB Protein Data Bank A resource for chemical, biochemical, and structural explorations of large and small biomolecules. Christine Zardecki, Shuchismita Dutta, David S. Goodsell, Maria Voigt, and Stephen K. Burley.
  43. BIOVIA, Dassault Systèmes, Discovery Studio visualizer, version 21.1.0 Dassault systèmes: San Diego; 2021.
  44. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera—A visualization system for exploratory research and analysis. Journal of Computational Chemistry. 2004;25(13):1605-1612. doi:10.1002/jcc.20084
  45. Laskowski RA, Jabłońska J, Pravda L, Vařeková RS, Thornton JM. PDBsum: Structural summaries of PDB entries. Protein Science. 2017;27(1):129-134. doi:10.1002/pro.3289
  46. Dallakyan S, Olson AJ. Small-Molecule Library Screening by Docking with PyRx. Methods in Molecular Biology. 2014:243-250. doi:10.1007/978-1-4939-2269-7_19
  47. PhysiologyMOL molecular graphics system, version 1.2r. Schrödinger, LLC: Portland, USA.
  48. Jendele L, Krivak R, Skoda P, Novotny M, Hoksza D. PrankWeb: a web server for ligand binding site prediction and visualization. Nucleic Acids Research. 2019;47(W1):W345-W349. doi:10.1093/nar/gkz424
  49. Kaleem S, Siddiqui S, Siddiqui HH, Badruddeen, Hussain A, Arshad M, et al. Eupalitin induces apoptosis in prostate carcinoma cells through ROS generation and increase of caspase‐3 activity. Cell Biology International. 2015;40(2):196-203. doi:10.1002/cbin.10552
  50. Schlessinger J. Receptor Tyrosine Kinases: Legacy of the First Two Decades. Cold Spring Harbor Perspectives in Biology. 2014;6(3):a008912-a008912. doi:10.1101/cshperspect.a008912
  51. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2023 update. Nucleic Acids Research. 2022;51(D1):D1373-D1380. doi:10.1093/nar/gkac956
  52. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nature Reviews Cancer. 2012;12(8):553-563. doi:10.1038/nrc3309
  53. SARKAR F, BANERJEE S, LI Y. Pancreatic cancer: Pathogenesis, prevention and treatment. Toxicology and Applied Pharmacology. 2007;224(3):326-336. doi:10.1016/j.taap.2006.11.007
  54. Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. New England Journal of Medicine. 2008;358(11):1160-1174. doi:10.1056/nejmra0707704
  55. Manu KA, Kuttan G. Punarnavine induces apoptosis in B16F-10 melanoma cells by inhibiting NF-kappaB signaling. Asian Pac J Cancer Prev. 2009;10:1031–7. PubMed: 20192578.
  56. Majd N, Nordin N, Hashim NM, Abd Rahman M, Hassan Z, Mohd Ali H. Liriodenine, an aporphine alkaloid from ­Enico­santhellum pulchrum, inhibits proliferation of human ovarian cancer cells through induction of apoptosis via the mitochondrial signaling pathway and blocking cell cycle progression. Drug Design, Development and Therapy. 2015:1437. doi:10.2147/dddt.s77727
  57. Knudsen ES, O’Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 2016;150(1):48-63. doi:10.1053/j.gastro.2015.08.056
  58. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, et al. Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology. 2012;142(4):730-733.e9. doi:10.1053/j.gastro.2011.12.042
  59. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission Possible? Nature Reviews Drug Discovery. 2014;13(11):828-851. doi:10.1038/nrd4389
  60. Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, et al. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncology. 2018;4(3):e173420. doi:10.1001/jamaoncol.2017.3420
  61. Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting. Advances in Cancer Research. 2005:29-86. doi:10.1016/s0065-230x(05)94002-5
  62. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer. Cancer Cell. 2003;4(4):257-262. doi:10.1016/s1535-6108(03)00248-4
  63. Bjornsti MA, Houghton PJ. Lost in translation. Cancer Cell. 2004;5(6):519-523. doi:10.1016/j.ccr.2004.05.027
  64. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 2004;23(16):2934-2949. doi:10.1038/sj.onc.1207515
  65. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network. Trends in Biochemical Sciences. 2002;27(9):462-467. doi:10.1016/s0968-0004(02)02166-7
  66. Zhou BP, Hung MC. Novel targets of Akt, p21, and MDM2. Seminars in Oncology. 2002;29(3Suppl11):62-70. doi:10.1053/sonc.2002.34057
  67. Fang X, Hong Y, Dai L, Qian Y, Zhu C, Wu B, et al. CRH promotes human colon cancer cell proliferation via IL‐6/JAK2/STAT3 signaling pathway and VEGF‐induced tumor angiogenesis. Molecular Carcinogenesis. 2017;56(11):2434-2445. doi:10.1002/mc.22691
  68. Zhang X, Lu H, Hong W, Liu L, Wang S, Zhou M, et al. Tyrphostin B42 attenuates trichostatin A-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling. Oncology Reports. 2018. doi:10.3892/or.2018.6241
  69. Vara JÁF, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treatment Reviews. 2004;30(2):193-204. doi:10.1016/j.ctrv.2003.07.007
  70. Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine & Growth Factor Reviews. 2016;31:1-15. doi:10.1016/j.cytogfr.2016.05.001
  71. Zhong Z, Wen Z, Darnell JE. Stat3: a STAT Family Member Activated by Tyrosine Phosphorylation in Response to Epidermal Growth Factor and Interleukin-6. Science. 1994;264(5155):95-98. doi:10.1126/science.8140422
  72. Ruff-Jamison S, Zhong Z, Wen Z, Chen K, Darnell JE, Cohen S. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. Journal of Biological Chemistry. 1994;269(35):21933-21935. doi:10.1016/s0021-9258(17)31735-0
  73. Wang D, Zheng X, Fu B, Nian Z, Qian Y, Sun R, et al. Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling. eBioMedicine. 2019;46:119-132. doi:10.1016/j.ebiom.2019.07.058
  74. Nguyen-Jackson HT, Li HS, Zhang H, Ohashi E, Watowich SS. G-CSF-activated STAT3 enhances production of the chemokine MIP-2 in bone marrow neutrophils. Journal of Leukocyte Biology. 2012;92(6):1215-1225. doi:10.1189/jlb.0312126
  75. Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nature Reviews Immunology. 2018;18(5):309-324. doi:10.1038/nri.2017.142
  76. Vara JÁF, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. Cancer Treatment Reviews. 2004;30(2):193-204. doi:10.1016/j.ctrv.2003.07.007